or
Bookmark and Share
Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
   
Document Number
US Patent 5385912
Issued Date
January 31, 1995
Link
Inventors
Amin; Dilip (North Wales, PA)
Scotese; Anthony C. (King of Prussia, PA)
Map
Abstract
This invention relates to polycyclic compounds containing two mono- and/or bicyclic rings and a basic tertiary amino group capable of forming an ammonium ion at biological pH and which reduces levels of serum cholesterol in the body without significantly reducing mevalonic metabolite synthesis. This invention relates also to pharmacological compositions and method of treatment for lowering serum cholesterol levels using the compounds of this invention. The compounds of this invention are described by the formula ##STR1## where Ar I is phenylene or naphthylene, Ar II is phenyl or naphthyl and A is 1-azabicyclo[2.2.2]octan-3-yl.
Drawing
Multicyclic tertiary amine polyaromatic squalene synthase inhibitors - US Patent 5385912 Drawing
Drawing from US Patent 5385912
Tags:
Description:
Amusing 0%
Clever 0%
Complex 0%
Efficient 0%
Historic 0%
Important 0%
Innovative 0%
Interesting 0%
Practical 0%
Simple 0%
Number of Claims:
12
Comments:
no comments yet
Owner
Published
January 31, 1995
Application Number
07/959,898
Filed
October 13, 1992
US Classification
514/305   546/133 546/137
Int'l Classification
C07D   453/02   (20060101)   C07D   471/00   (20060101)   C07D   453/00   (20060101)   C07D   471/18   (20060101)  
Examiner
Assistant Examiner
Parent Case
This application is a continuation-in-part application of U.S. patent application Ser. No. 07/667,686, filed Mar. 8, 1991 now abandoned and a continuation-in-part application of PCT Application having Ser. No. PCT/US92/01773, filed Mar. 3, 1992.
USPTO Field of Search
546/133   546/137   514/305  
Related Patents
5919793 - Heterocyclic derivatives - Owned by Zeneca Limited (London,GB)

Compounds of formula (I) wherein R.sup.1 is hydrogen or hydroxy; R.sup.2 is hydrogen; or R.sup.1 and R.sup.2 are joined together so that CR.sup.1 14 CR.sup.2 is a double bond; X is selected from --Ch.sub.2 CH.sub.2 --, --C.dbd.CH--, --C.tbd.C--, --CH.sub.2 O--, --OCH.sub.2, CH.sub.2 NH--, --NHCH.sub.2 --, --CH.sub.2 CO--, --COCH.sub.2 --, --CH.sub.2 S(O).sub.n -- and --S(O).sub.n CH.sub.2 -- (wherein n is 0, 1 or 2); Ar is phenyl which bears one or more substituents independently selected from the groups (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkoxycarbonyl, (1-6C)alkoxycarbonyl(1-6C)alkyl, (1-6C)alkoxy(1-6C)alkyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, carbamoyl, (1-6C) alkylcarbamoyl, di-[(1-6C)alkyl]carbamoyl, (1-6C)alkenyl and oxime derivatives thereof and O--(1-6C)alkyl ethers of said oximes (1-6C)alkylthio, (1-6C)alkylsulphinyl and (1-6C)alkylsulphonyl when substituted by one or more groups selected from (1-6C)alkoxycarbonyl, (1-6C)alkanoyl and oxime derivatives thereof and O-(1-6C)alkyl ethers of said oxime derivatives, (1-6C)alkanoylamimo, (1-6C)alkanoyloxy, (1-6C)alkanoyloxy(1-6)alkyl, carbamoyl, N-(1-6C)alkylcarbamoyl, N,N-di[(1-6C)alkyl]carbamoyl, amino, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxy, (2-6C)alkenyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, halogeno(1-6C)alkyl (2-6C)alkenyl, (2-6C)alkynyl, phenyl, phenoxy, cyano, nitro, hydroxy and carboxy; and wherein Ar may bear further substituents; and their pharmaceutically acceptable salts inhibit squalene synthese and are hence useful in lowering cholesterol levels in blood plasma Processes for preparing compounds of formula (I) are also referred to as well as pharmaceutical compositions containing them and their use in medicine.

6872834 - Phenyl-substituted indoles and indazoles - Owned by Ortho-McNeil Pharmaceutical, Inc. (Raritan, NJ)

The invention features pharmaceutically-active indoles and indazoles that are substituted with phenyl, methods of making them, and methods of using them.

7160876 - Fused bicycloheterocycle substituted quinuclidine derivatives - Owned by Abbott Laboratories (Abbott Park, IL)

Compounds of formula (I) ##STR00001## wherein n is 0, 1, or 2; X is O, S, --NH--, and --N-alkyl-; Ar.sup.1 is a 6-membered aromatic ring; and Ar.sup.2 is a fused bicycloheterocycle. The compounds are useful in treating conditions or disorders prevented by or ameliorated by .alpha.7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.

5776951 - Anti-atherosclerotic diaryl compounds - Owned by Glaxo Wellcome Inc. (Research Triangle Park, NC)

The present invention is concerned with diaryl compounds of formula (l) and their use in medical therapy, particularly in the prophylaxis or treatment of a clinical condition for which an ACAT inhibitor is indicated, such as hyperlipidaema or atherosclerosis. The invention also relates to pharmaceutical compositions and processes for the preparation of compounds according to the invention. ##STR1##

7579362 - Aza-bicycloalkyl ethers and their use as alpha7-nAChR agonists - Owned by Novartis AG (Basel,CH)

The present invention relates to 1-aza-bicycloalkyl derivatives of formula I, ##STR00001## wherein X is CH.sub.2 or a single bond; Y is a group of formula ##STR00002## and wherein R has the meanings as defined in the specification, which compounds are alpha 7 nicotinic acetylcholine receptor (nAChR) agonists; to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.

Claims
Description
About| FAQs| Terms & Disclaimer| Link to Us| Contact Us